Tux Pacific, founder and CEO of Entropy, has announced the wind-up of the crypto startup after four years of operations, multiple pivots, and two rounds of layoffs. The company, backed by A16z, will return remaining capital to investors, with final steps subject to approvals.
Pacific revealed that the team spent the latter half of 2025 building a crypto automation platform leveraging threshold cryptography, trusted execution environments (TEEs), and artificial intelligence (AI) integrations. However, the core product was judged not to be venture scale, limiting further fundraising possibilities. As a result, Pacific decided to close the company.
Capital Return and Team Support
Investors will receive their capital back after necessary approvals. Pacific also offered support for remaining staff, helping them transition to new roles. The founder stated that the wind-up process is underway with transparency.
A Radical Pivot to Pharmaceuticals
Following a planned break, Pacific intends to shift focus to pharmaceutical research, specifically estradiol formulations and hormone delivery systems for women and transgender hormone replacement therapy (HRT). The founder invited pharma and medical experts to reach out, signaling a deep personal and professional interest in addressing gaps in hormone therapy.
This pivot from crypto to pharma highlights a growing trend of tech founders exploring life sciences after facing limitations in the blockchain space. Pacific's background in cryptography and automation could bring unique insights to drug delivery systems.
Looking Ahead
Pacific remains accessible via public channels for hiring of former team members and collaboration with pharma experts. The move underscores that even well-funded crypto startups can fail to scale, but founders can redirect their skills to promising fields like biotechnology.